




RealRate

PHARMACEUTICAL 2017

Ocuphire Pharma Inc.
Rank 94 of 292





RealRate

PHARMACEUTICAL 2017

Ocuphire Pharma Inc.
Rank 94 of 292



The relative strengths and weaknesses of Ocuphire Pharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ocuphire Pharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 81% points. The greatest weakness of Ocuphire Pharma Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 160%, being 157% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	20,924
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	31
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3,985
Other Net Income	7,106
Other Revenues	0
Property and Equipment	89
Research and Development	10,089
Selling, General and Administrative Expense	6,324

Output Variable	Value in 1000 USD
Assets	21,044
Liabilities	3,985
Expenses	16,413
Revenues	0
Stockholders Equity	17,058
Net Income	-9,307
Comprehensive Net Income	-9,307
Economic Capital Ratio	160%